Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name TTI-622
Trade Name
Drug Descriptions

TTI-622 is a fusion protein consisting of SIRPa fused to the human IgG4 Fc region, that binds to CD47 and blocks inhibitory signaling to macrophages, resulting in increased phagocytosis of tumor cells (Cancer Res 2018;78(13 Suppl):Abstract nr 2709).

DrugClasses CD47 Antibody 26 Immune Checkpoint Inhibitor 151
CAS Registry Number NA
NCIT ID C150756


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Daratumumab + TTI-622 Daratumumab TTI-622 0 1
Pegylated liposomal doxorubicin + TTI-622 Pegylated liposomal doxorubicin TTI-622 0 1
Pembrolizumab + TTI-622 Pembrolizumab TTI-622 0 1
TTI-622 TTI-622 0 1

Additional content available in CKB BOOST